Daawooyinka Ka-hortagga Kansarka Acalabrutinib: Daaweynta loogu talagalay CLL / SLL / MCL - AASraw
AASraw waxay soo saartaa Cannabidiol (CBD) budada iyo Hemp Saliida Muhiimka ah!

Dawooyinka Kahortaga Kansarka Acalabrutinib

 

  1. Acalabrutinib Backgroud
  2. Faallooyinka Acalabrutinib
  3. Daaweynta Acalabrutinib (Waxaa loo Isticmaalay)
  4. Acalabrutinib Mechanism of Action
  5. Maxay yihiin waxyeelooyinka suurtogalka ah ee Acalabrutinib?
  6. Acalabrutinib VS Ibrutinib
  7. Cilmi-baaris: Acalabrutinib On Daweynta Cudurka 'lymphocytic leukemia' (CLL)

 

Acalabrutinib Backgroud

Ilaa hadda, acalabrutinib waxaa loo isticmaalay tijaabooyinka lagu baranayo daaweynta B-All, Myelofibrosis, Cancer Ovarian, Multiple Myeloma, iyo Hodgkin Lymphoma, iyo kuwo kale.

Laga bilaabo Oktoobar 31, 2017 FDA waxay ansixisay Astra Zeneca ee afka laga maamulo Calquence (acalabrutinib). Xakamaynta Bruton Tyrosine Kinase (BTK) ee loogu talagalay daaweynta cudurka lempmia lempmia, lymphocytic lymphoma, iyo bukaanka qaangaarka ah ee qaba Mantle Cell Lymphoma (MCL) oo horeyba u helay ugu yaraan hal daaweyn hore.

Sidoo kale loo yaqaan ACP-196, acalabrutinib sidoo kale waxaa loo tixgeliyaa jiilka labaad ee BTK inhibitor maxaa yeelay si caqli gal ah ayaa loogu talagalay inuu ka awood iyo xulo badan yahay ibrutinib, aragti ahaan waxaa lafilayaa inuu muujiyo waxyeelo yar oo ka timid dhanka yareynta saameynta daawadayaasha ee bartilmaameedyada aan aheyn BTK.

Si kastaba ha noqotee, acalabrutinib waxaa lagu ansixiyay dariiqa la ansixiyay ee FDA ee dardargelinta, kaas oo ku saleysan heerka jawaabta guud iyo wejiga hore ee oggolaanshaha daawooyinka daweeya xaaladaha halista ah ama / iyo kuwaas oo buuxiya baahi caafimaad oo aan la daboolin oo ku saleysan dhammaadka beddelka. Sii wadida ogolaanshaha acalabrutinib ee tilmaanta hada la aqbalay ayaa laga yaabaa inay ku xirnaato xaqiijinta socota iyo sharaxaada faa iidada caafimaad ee tijaabooyinka qirashada.

Intaa waxaa sii dheer, FDA waxay siisay daawadan Dib-u-eegista Mudnaanta iyo tilmaamaha Daaweynta Burburka. Waxa kale oo ay heshay tilmaamista Dawada Agoonta, taas oo dhiirrigelin siisa caawinta iyo dhiirigelinta horumarinta daawooyinka cudurada dhifka ah. Waqtigaan, in ka badan 35 tijaabooyin caafimaad oo ka socda 40 dal oo in ka badan 2500 bukaanno ah ayaa socda ama lagu dhammeeyey iyada oo la tixraacayo cilmi baaris dheeri ah oo ku saabsan faham wanaagsan iyo ballaarinta isticmaalka daaweynta ee acalabrutinib 5.

 

Acalabrutinib Reviews

Acalabrutinib (CAS:1420477-60-6), oo lagu suuq geeyo magaca loo yaqaan 'Calquence®' ee Mareykanka iyo Kanada, waa jiil labaad oo loo yaqaan 'molecule inhibitor' ee Bruton's tyrosine kinase (BTK). Marka la qaato maamulka afka, acalabrutinib waxay ku xidhan tahay oo si aan macquul ahayn u xakameyneysaa waxqabadka BTK taas oo ka hortageysa firfircoonaanta B-cell iyo B-cell-dhexdhexaadinta. Ficilkani wuxuu horseedayaa kahortaga koritaanka unugyada halista ah ee B ee ka bad badiya BTK. BTK ayaa looga baahan yahay calaamadaha B-cell, wuxuu door muhiim ah ka ciyaaraa koriinka B-cell, waxaana si xad dhaaf ah looga muujiyaa dhowr xumaan-darro B-cell ah, oo ay ku jiraan CLL / SLL. Muujinta BTK ee unugyada burooyinka waxay la xiriirtaa kordhinta iyo noolaanshaha. Jiilka labaad ee BTK inhibitor, acalabrutinib waxaa loogu talagalay in lagu kordhiyo saameynta BTK isla markaana la yareeyo waxqabadka bartilmaameedka ee TEC (Tec Protein Tyrosine Kinase), EGFR (qalliinka koritaanka epidermal factor factor), iyo ITK (interleukin-2-inducible T- unug kinase). Jiilka ugu horreeya ee BTK inhibitor, ibrutinib (Imbruvica), ayaa ka maqan qeexitaankan taas oo keenta dhacdooyin badan oo saameyn xun leh. Marka lagu daro CLL / SLL, acalabrutinib waxaa loo oggolaaday Mantle Cell Lymphoma (MCL). Shabakadda National Cancer Center (NCCN) Tilmaamaha ayaa acalabrutinib ku leh ama aan lahayn obinituzumab oo ah daaweynta ugu horreysa ee daaweynta CLL / SLL iyo sidoo kale ku habboon isticmaalka ku noqoshada ama diidmada (R / R) CLL.

 

Acalabrutinib Daaweynta (Loo Adeegsaday)

Acalabrutinib waxaa loo isticmaalaa in lagu daaweeyo dadka qaba unugyada manfacyada unugyada jirka (MCL; kansar si dhakhso ah u koraya oo ka bilaabmaya unugyada nidaamka difaaca jirka) kuwaas oo horey loogu daaweeyay ugu yaraan hal daawo kale oo kiimiko ah.

Acalabrutinib waxaa loo isticmaalaa kaligiis ama obinutuzumab (Gazyva) lagu daaweeyaa Cudurka sanbabada ee daba-dheeraada (CLL; nooc ka mid ah kansarka ka bilaabma unugyada dhiigga cad) iyo lymphocytic lymphoma (SLL: nooc ka mid ah kansarka ka bilaabmaa unugyada dhiiga cad).

Acalabrutinib waxay kujirtaa nooc daawooyin ah oo loo yaqaan kinase inhibitors. Waxay ku shaqeysaa iyadoo la xakameynayo ficilka borotiinka aan caadiga ahayn ee tilmaamaya unugyada kansarka inay tarmaan. Tani waxay kaa caawinaysaa joojinta faafitaanka unugyada kansarka.

 

Acalabrutinib hab Of Action

Mantle Cell Lymphoma (MCL) waa nooc dhif ah oo weli dagaal badan oo ah B-cell non-Hodgkin lymphoma (NHL) oo leh saadaal xumo. Kadib, soo noqoshada waxay ku badan tahay bukaanka MCL waxayna ugu dambeyntii u taagan tahay horumarka cudurka.

Lymphoma wuxuu dhacaa marka nidaamka difaaca jirka ee 'lymphocytes' koraan oo u tarmo si aan la xakameyn karin. Noocyada noocan ah ee kansarka qaba waxay u safri karaan qaybo badan oo jidhka ka mid ah, oo ay ku jiraan qanjidhada qanjidhada, beeryarada, dhuuxa lafta, dhiigga, iyo xubnaha kale ee ay ku tarmi karaan oo samayn karaan tiro (loo yaqaan) buro. Mid ka mid ah noocyada waaweyn ee lymphocytes ee isku beddeli kara qanjidhada kansarka qaba waa jirka u gaarka ah B-lymphocytes (B-cells).

Bruton Tyrosine Kinase (BTK) waa molecule tilmaamaysa B-cell antigen reseptor iyo wadiiqooyinka cytokine receptor. Calaamadaha noocan oo kale ah ee BTK wuxuu sababa kicinta dariiqyada lagama maarmaanka u ah faafitaanka unugyada B, tahriibinta, kiimotakisyada, iyo adhesion-ka.

Acalabrutinib waa xakamey yar oo molecule ah oo ka hortaga BTK. Labadaba acalabrutinib iyo dheef-shiid kiimikaad firfircoon, ACP-5862, waxay u dhaqmaan si ay u sameeyaan isku xirnaan leh haraaga cysteine ​​(Cys481) ee goobta firfircoon ee BTK, taasoo horseedaysa xakameynta dhaqdhaqaaqa BTK enzymatic. Natiijo ahaan, acalabrutinib wuxuu xakameynayaa dhaqdhaqaaqa BTK ee dhexdhexaadinta. calaamadeynta borotiinnada CD86 iyo CD69, oo aakhirka joojiya badashada iyo badbaadada unugyada halista ah ee B-cell.

Halka ibrutinib sida caadiga ah loo aqoonsan yahay inuu yahay fasalka koowaad ee fasalka BTK, acalabrutinib waxaa loo tixgeliyaa inuu yahay jiilka labaad ee BTK horjooge ugu horeyn sababtoo ah waxay muujineysaa xulasho sarreysa iyo xakameynta howlaha bartilmaameedka ah ee BTK halka ay heysato IC50 aad u weyn ama haddii kale aysan jirin wax xakameyn ah howlaha kinase ee ITK, EGFR, ERBB2, ERBB4, JAK3, BLK, FGR, FYN, HCK, LCK, LYN, SRC, iyo YES1.

Saamayn ahaan, acalabrutinib ayaa si caqli gal ah loogu talagalay in laga awood roonaado lagana xusho ibrutinib, intaasoo dhan iyadoo la muujinayo saameyn yar oo aan fiicneyn - aragti ahaan - sababtoo ah daroogada oo laga yareeyay saameynta bartilmaameedka.

AASraw waa soo saaraha xirfadlaha ah ee Acalabrutinib.

Fadlan halkan guji si aad u hesho macluumaadka xigashada: Nala soo xiriir

 

Maxay yihiin waxyeelooyinka suurtogalka ah ee Acalabrutinib?

Acalabrutinib waxay sababi kartaa waxyeelo daran, oo ay ka mid yihiin:

Infekshanada halista ah waxay dhici karaan inta lagu jiro daaweynta Acalabrutinib waxayna u horseedi kartaa dhimasho. Bixiyaha daryeelka caafimaadkaaga ayaa kuu qori kara dawooyinka qaarkood haddii aad halis dheeraad ah ugu jirto infekshinnada aad qaaddo. U sheeg dhakhtarkaaga isla markiiba haddii aad leedahay wax calaamado ama astaamo ah oo infekshin ah, oo ay ku jiraan qandho, qarqaryo, ama calaamado u eg hargab.

Dhibaatooyinka dhiig-baxa (dhiig-baxa) waxay dhici karaan inta lagu jiro daweynta Acalabrutinib waxayna noqon kartaa mid culus waxayna u horseedi kartaa dhimasho. Khatartaada dhiig-baxa way sii kordheysaa haddii aad sidoo kale qaadanaysid daawo khafiifisa dhiigga. U sheeg daryeel bixiyahaaga caafimaadka haddii aad isku aragto wax calaamado ah ama astaamo dhiigbax ah, oo ay ku jiraan dhiig saxaradaada ku jira ama saxaradaada madow (waxay u egtahay daamur), kaadi casaan ama bunni ah, dhiigbax lama filaan ah ama dhiigbax daran ama aanad xakamayn karin, matagayn dhiig ama matag waxay u egtahay qaxwada, qufaca dhiigga ama xinjirowga dhiigga, wareer, daciifnimo, jahwareer, isbeddelada hadalkaaga, madax xanuun muddo dheer soconaya, ama nabarro ama calaamadaha maqaarka casaanka ama guduudka

Hoos u dhaca tirinta unugyada dhiiga. Dhimashada dhiigga (unugyada dhiigga cad, platelets, iyo unugyada dhiigga cas) waxay ku badan yihiin Acalabrutinib, laakiin sidoo kale waxay noqon karaan kuwo daran. Bixiyahaaga daryeel caafimaad waa inuu sameeyaa baaritaano dhiig si loo hubiyo tirinta dhiigaaga si joogto ah inta lagu jiro daweynta Acalabrutinib.

Kansarka labaad ee aasaasiga ah. Kansarro cusub ayaa ku dhacay dadka inta lagu jiro daaweynta Acalabrutinib, oo ay ku jiraan kansarrada maqaarka ama xubnaha kale. Bixiyahaaga daryeelka caafimaad ayaa kaa hubin doona kansarka maqaarka inta lagu jiro daaweynta Acalabrutinib. Isticmaal ka hortagga qorraxda marka aad bannaanka joogto iftiinka qoraxda.

Dhibaatooyinka laxanka wadnaha (fibrillation atrial flutter) ayaa ku dhacay dadka lagu daaweeyo Acalabrutinib. U sheeg daryeel caafimaad bixiyahaaga haddii aad isku aragto mid ka mid ah calaamadaha ama astaamaha soo socda: garaaca wadnaha oo dhakhso ah ama aan caadi ahayn, wareer, dareemid suuxdin, raaxo-darrada laabta, ama neefta oo ku qabata

Saameynaha ugu caansan ee Acalabrutinib waxaa ka mid ah madax xanuun, shuban, murqo iyo kalagoys xanuun, infekshinka mareenka sare, iyo nabar.

Kuwani dhammaantood maahan waxyeellooyinka suurtagalka ah ee Acalabrutinib. Wac dhakhtarkaaga si aad uga hesho talo caafimaad wixii ku saabsan dhibaatooyinka soo raaca. Waxaad ku soo wargelin kartaa waxyeellooyinkaaga FDA 1-800-FDA-1088.

 

Acalabrutinib

 

 

Acalabrutinib VS Ibrutinib

BTK ayaa door muhiim ah ka ciyaareysa dariiqa tilmaanta soo-dhaweynta B-cell; acalabrutinib waxay ku xirtaa BTK si aan macquul aheyn waxayna xakameysaa waxqabadkeeda. Daawada waxaa loogu talagalay inay noqoto mid ka doorbid badan BTK inhibitor, iskuday si loo yareeyo qaar ka mid ah sunta daaweynta xaddidan ee badanaa lagu arko ibrutinib. Sida laga soo xigtay Dr. Brown, "Acalabrutinib waa ka-hortagga BTK ee xulashada dadka qaba cudurada faafa, gaar ahaan arrimaha wadnaha."

Xogta waxtarka leh waxay u egtahay mid udhaxeysa acalabrutinib iyo ibrutinib, in kasta oo dabagalku uu ka dheer yahay ibrutinib, Dr. Brown ayaa sii waday. Sidaa darteed, farqiga ugu muhiimsan ee u dhexeeya daawooyinka wuxuu kujiraa astaamaha saameyntooda. Ibrutinib waxay u egtahay in si liidata loogu dulqaato bukaanada waaweyn waxayna la xiriirtaa heerarka sare ee fibrillation-ka iyo dhiig karka. "Acalabrutinib ayaa sifiican uga dulqaadasho badan" marka loo eego ibrutinib], sidaa darteed waxaan u doorbidayaa si gaar ah, gaar ahaan bukaankayga waayeelka ah, "ayay tiri.

Ansixinta daroogada ee CLL, oo ​​la siiyay Noofambar 2019, waxay ku saleysneyd xogta badbaadada iyo waxtarka leh ee ka soo baxday falanqaynta ku meel gaarka ah ee tijaabada ELEVATE-TN ee bukaanada aan horay loo daaweynin CLL iyo tijaabada ASCEND ee bukaanada qaba CLL soo noqoshada ama diidmada ah. Labada tijaaboba, acalabrutinib muujiyey badbaadin horumar la'aan ah oo ka-sarreysa marka la barbar dhigo daaweynta caadiga ah, iyo muuqaal dulqaad leh oo wanaagsan. In tijaabada ELEVATE-TN, gaar ahaan, acalabrutinib oo lagu daro obinutuzumab iyo daaweynta monotherapy waxay yareysay halista cudurka sii socoshada ama dhimashada 90% iyo 80%, siday u kala horreeyaan.

"U dulqaadashada ayaa weli ah arrin ka jirta muuqaalka daaweynta ee hadda CLL, taas oo u baahan karta daaweyn socota sanado badan," ayuu yiri Jeff Sharman, MD, Agaasimaha Cilmi baarista ee Dooxada Willamette Kansarka Machadka, Agaasimaha Caafimaadka ee Cilmi-baarista Hematology ee Shabakada Oncology ee Mareykanka, iyo hogaamiyaha qoraaga tijaabada ELEVATE-TN, war-saxaafadeed. "ELEVATE-TN iyo ASCEND tijaabooyin isbarbar dhiga [acalabrutinib] iyo nidaamyada daaweynta ee inta badan la isticmaalo, [acalabrutinib] waxay muujiyeen horumarin caafimaad oo micno leh oo ku saabsan badbaadada horusocod la'aanta ah ee bukaanada ku teedsan goobaha kala duwan, iyadoo la ilaalinayo dulqaadkeeda wanaagsan iyo astaantiisa amniga."

 

Research: Acalabrutinib Daaweynta Cudurka sanbabada ee daba-dheeraada (CLL)  

(1) Cudurka sanbabada ee daba-dheeraada (CLL)

Cudurka sanbabada ee daba-dheeraada (CLL), kansarka ugu weyn ee leukaemia, waa neoplasm loo yaqaan 'clonal neoplasm' oo ka kooban monomorphic yar yar oo qaangaar ah oo B ah oo wada shaqeeya CD5 iyo CD23. Muuqaalka daaweynta ee CLL ayaa si aad ah isu beddelay sannadihii la soo dhaafay. Daawooyinka lagu bartilmaameedsanayo borotiinada marinka unugga B unugyada antigen receptor (BCR), sida ibrutinib, waxay muujiyeen horumar laga sameeyay horumarka xorta ah iyo guud ahaan badbaadada, oo ay ku jiraan bukaanada qaba cudurka halista badan. Inkasta oo daawooyinkani ay isbeddeleen qaabka daaweynta ee bukaanada qaba CLL, daaweynta soo-gaadhista iyo xoojinta ibrutinib waa la xaddidi karaa iyada oo ay ugu wacan tahay astaanta saameynta iyo sunta daaweynta la xiriirta. Acalabrutinib, jiil labaad iyo ka-doorbid badan Bruton's tyrosine kinase (BTK) inhibitor, ayaa loo sameeyay si loo kordhiyo waxtarka iyadoo la yareynayo dhacdooyinka xun ee la xiriira ibrutinib ee loo maleynayo inay yihiin kuwa labaad ee saameynta bartilmaameedka ibrutinib. Dib-u-eegiddani waxay soo koobi doontaa horumarka, qiimeynta daaweynta kahor, iyo tijaabooyinka caafimaad ee muhiimka ah ee muujiyey waxtarka acalabrutinib iyo astaanta sunta ee CLL.

 

(2) Daraasadaha Preclinical ee Acalabrutinib ee CLL

Dhowr daraasadood oo horay loo sameeyay waxay muujiyeen waxtarka acalabrutinib ee ka hortagga BTK. Markii lagu tijaabiyay dhiigga aadanaha oo dhan, acalabrutinib wuxuu lahaa qalab xakameyn BTK marka loo eego ibrutinib. Ibrutinib waxaa lagu ogaadey inuu sababayo apoptosis kordhinta unugyada CLL marka la barbardhigo acalabrutinib, taas oo lagu sharxi karo saameynta bartilmaameedka ee ibrutinib. Acalabrutinib wuxuu saameyn yar ku yeeshay unugyada T-ga ee caafimaadka qaba sababo la xiriira xulashadiisa marka loo eego ibrutinib.

Saamaynta ladagaalanka ladagaallanka burooyinka ee acalabrutinib waxaa laguqiimeeyay laba nooc oo muril dil ah: nooc TCL1 ah oo korsasho korsasho ah iyo qaab xayeysiin bini aadam CLL ah. Acalabrutinib waxaa loo muujiyey inay ka hortageyso calaamadaha BCR iyo daaweynta acalabrutinib waxay la xiriirtay koror aad u weyn oo noolaanshaha marka la barbar dhigo jiirka aan la daaweynin (dhexdhexaad 81 maalmood vs 59 maalmood, p = 0.02). Acalabrutinib sidoo kale waxay sababtay hoos u dhac weyn unugyada sii kordhaya iyo culeyska burooyinka guud ee beeryarada.

Isdhexgalka Acalabrutinib iyo anti-CD20 monoclonal antibodies sidoo kale waa la qiimeeyay. Ibrutinib waxay faragalin ku yeelan kartaa dhowr ka mid ah farsamooyinka ficil-celinta antibodies-ka CD20-ka oo si gaar ah u horjoogsanaya unugyada unugyada anti-ku-tiirsan ee cytotoxicity iyo phagocytosis taas oo yareyn karta saameyntooda ka hortagga burooyinka. Waxayna ogaatay in aysan faragalin ku sameynin howlahaan, waxay u badan tahay saameynta ugu yar ee bartilmaameedka acalabrutinib. In kasta oo isku darka acalabrutinib ee anti-CD20 monoclonal antibody aan lagu baran daraasad qaab vivo ah, dhowr waji 2 iyo wajiga 3 daraasadood ayaa socda ama la dhammeeyay kuwaas oo muujinaya waxtarka acalabrutinib oo lagu daro anti-CD20 monoclonal antibody.

Isku-darka kale ee acalabrutinib ayaa lagu bartay labadaba qaababka 'vitro' iyo 'vivo'. Acalabrutinib waxaa lagu daray PI3Kdelta inhibitor (ACP-319) oo ah qaab murugo leh oo CLL ah waxayna muujisay hoos u dhac weyn oo ku yimid kordhinta burooyinka, calaamadaha NF-KB iyo muujinta BCL-xL iyo MCL-1 marka loo eego daaweynta monotherapy. Isku-darkaan waxaa lagu muujiyey inuu kordhay apoptosis marka la barbardhigo daroogada oo keliya, taasoo soo jeedinaysa xiriir is-dhexgal ah oo la mid ah kan lagu arkay ibrutinib iyo venetoclax. Tijaabadii ku xigtay ee vivo waxay muujisay badbaado dheer oo jiir ah oo lagu daaweeyay acalabrutinib iyo venetoclax labadaba marka la barbar dhigo daroogada oo keliya.

 

(3) Gabagabada

Isku soo wada duuboo, daraasadaha lagu sharraxay waxay muujinayaan in acalabrutinib uu leeyahay waxtar weyn oo ku saabsan daaweynta CLL, labadaba daweynta daaweynta iyo dib u soo noqoshada labadaba. Ma cadda in waxtarka uu la mid yahay ama ka sarreeyo ibrutinib iyo daraasadaha ayaa socda iyagoo isku dayaya in ay sii barbardhigaan wakiilladan. In kasta oo sunta caadiga ah ee la xiriirta BTK sida dhiigbaxa ama dhacdooyinka fibrillation atrial ay yihiin dhacdooyin aan badnayn, acalabrutinib wuxuu leeyahay astaan ​​AE gaar ah, gaar ahaan madax xanuun, oo u baahan kormeer taxaddar leh iyo khibrad maamul. Xogta laga helayo daraasadaha socda ee lagu qiimeynayo isku darka acalabrutinib ayaa gacan ka geysan doonta sidii loo sii qeexi lahaa kaalinteeda maamulka CLL. Ugu dambeyntiina, oggolaanshaha FDA, waayo-aragnimada dhabta ah ee acalabrutinib ayaa gacan ka geysan doonta sidii loo sii qeexi lahaa astaanta sumowga.

AASraw waa soo saaraha xirfadlaha ah ee Acalabrutinib.

Fadlan halkan guji si aad u hesho macluumaadka xigashada: Nala soo xiriir

 

Tixraaca

[1] Maamulka Cuntada iyo Dawooyinka ee Mareykanka. Mashruuca Orbis: FDA waxay ansixisay acalabrutinib loogu talagalay CLL iyo SLL. Waxaa laga heli karaa https://www.fda.gov/drugs/resources-information-approved-drugs/project-orbis-fda-approves-acalabrutinib-cll-and-sll. La helay Abriil 29, 2020.

[2] Sharman JP, Banerji V, Fogliatto LM, et al. ELEVATE-TN: Wajiga 3 ee daraasadda acalabrutinib oo lagu daro obinutuzumab ama kelidii vs obinutuzumab oo lagu daray chlorambucil ee bukaanada qaba daaweyn-naive chronic lymphocytic leukemia. Dhiigga 2019; 134 (alaabada 1): 31.

[3] Warsaxaafadeedka AstraZeneca. Calquence ayaa laga ansixiyay Mareykanka bukaanka qaangaarka ah ee qaba lempmia lempmia daba dheeraata. Waxaa laga heli karaa https://www.astrazeneca.com/media-centre/press-releases/2019/calquence-approved-in-the-us-for-adult-patients-with-chronic-lymphocytic-leukaemia-21112019.html. La helay Abriil 29, 2020.

[4] Goede V, Fischer K, Busch R, et al. Obinutuzumab oo lagu daray chlorambucil ee bukaanada qaba CLL iyo xaaladaha wada noolaanshaha. N Engl J Med. 2014; 370 (12): 1101–1110. doi: 10.1056 / NEJMoa1313984.

[5] Parikh SA, Muchtar E, Laplant B, iyo al. Daraasad marxalad kala sooc ah oo la isbarbardhigayo acalabrutinib oo leh ama aan lahayn obinutuzumab ee daaweynta bukaanka marxaladda hore ee halista sare leh oo leh Chronic Lymphocytic Leukemia (CLL) ama Little Lymphocytic Lymphoma (SLL). Dhiig. 2; 2019 (Supplement_134): 1. doi: 4306 / dhiig-10.1182-2019.

[6] Covey T, Gulranjani M, Cheung J, et al. Qiimeynta Pharmacodynamic ee acalabrutinib ee soo noqoshada / diidmada iyo bukaanka daaweynta-naafanimada leh ee leh Lymphocytic Leukemia Chronic (CLL) wajiga 1/2 ACE-CL-001 Study. Dhiig. 2017; 130 (Supplement1): 1741. doi: 10.1182 / blood.V130.Suppl_1.1741.1741.

[7] Byrd JC, Brown JR, O'Brien S, iyo al. Ibrutinib iyo ofatumumab oo horey loogu daweeyey cudurka lempmia lempmia ee joogtada ah. N Engl J Med. 2014; 371 (3): 213–223. doi: 10.1056 / NEJMoa1400376.

[8] Woyach JA, Bojnik E, Ruppert AS, iyo al. Shaqada Bruton ee tyrosine kinase (BTK) waxay muhiim u tahay horumarinta iyo ballaarinta lempmia lempmia lymphocytic chronic (CLL). Dhiig. 2014; 123 (8): 1207-1213. doi: 10.1182 / dhiig-2013-07-515361.

[9] Chiorazzi N, Rai KR, Ferrarini M. Cudurka 'lempmia lempmia lymphocytic chronic'. N Engl J Med. 2005; 352 (8): 804-815. doi: 10.1056 / NEJMra041720.

[10] Barr PM, Robak T, Owen C, iyo al. Waxtarka joogtada ah iyo dabagalka bukaan socodka ee faahfaahsan ee daaweynta koowaad ee daaweynta ibrutinib ee bukaanada waayeelka ah ee leh lempmia lempmia lymphocytic daba dheeraatay: natiijooyinka wajiga 3 ee la dheereeyay ee ka imanaya RESONATE-2. Haematologica. 2018; 103 (9): 1502–1510. doi: 10.3324 / haematol.2018.192328.

[11] Herman SEM, Montraveta A, Niemann CU, iyo al. Bruton Tyrosine Kinase (BTK) inhibitor ACP-196 wuxuu muujiyaa waxqabadka kiliinikada ee laba nooc oo jiir ah oo ah lempmia lempmia lymphocytic chronic. Dhiig. 2015; 126 (23): 2920. doi: 10.1182 / dhiig.V126.23.2920.2920.

 

 

1 jecel yahay
2074 Views

Waxaa kaloo laga yaabaa

Comments are closed.